Grilled Cheese

ExploreLog inSign up
Terms of UsePrivacy PolicyCommunity StandardsHelpGet the app

Grilled Cheese is a product of Village Compute

Version devBuilt at: 2026-10-12 04:31:30 EDT

Explore

PostsPeople
LatestRanked
@rcatanho.bsky.socialSep 15, 2026, 2:30 PM

Uso de anbenitamab neoadyuvante y HB1801 en pacientes con cáncer de mama mejora la respuesta completa patológica total versus la terapia estándar con un perfil de seguridad manejable #anbenitamab #HB1801 #breastcancer #ERBB2 jamanetwork.com/journals/jam...

@medchemexpress.bsky.socialSep 11, 2026, 9:00 AM

The #FDA has granted accelerated approval to #sevabertinib (#Hyrnuo) for adults with locally advanced/metastatic non-squamous NSCLC harboring activating HER2 (#ERBB2) tyrosine kinase domain mutations.

SOHO-01 trial: 75% objective response rate in patients who had not received prior systemic therapy

@jamaoncology.comSep 7, 2026, 4:00 PM

Among patients with #ERBB2-positive #BreastCancer, neoadjuvant anbenitamab plus HB1801 was associated with a higher total pathologic complete response rate vs trastuzumab, pertuzumab, and docetaxel, with similar grade 3 or 4 toxic effects.

ja.ma/46FBax8

JAMA Oncology: RCT of Anbenitamab+HB1801 for ERBB2-positive breast cancer. 521 female patients (median age 52) in 61 Chinese hospitals. Anbenitamab+HB1801 (62.4% tpCR) outperformed THP (51.2% tpCR), with an 11.4% absolute difference (P=.004).